Real-world evidence on siponimod treatment in patients with secondary progressive multiple sclerosis

BackgroundTherapeutic options targeting inflammation in multiple sclerosis (MS) have evolved rapidly for relapsing–remitting MS, whereas few therapies are available for progressive forms of MS, in particular secondary progressive MS (SPMS). The approval of siponimod for SPMS has allowed for optimism...

Full description

Saved in:
Bibliographic Details
Published in:Neurological research and practice 2022-11, Vol.4 (1), p.55-11, Article 55
Main Authors: Regner-Nelke, Liesa, Pawlitzki, Marc, Willison, Alice, Rolfes, Leoni, Oezalp, Sinem-Hilal, Nelke, Christopher, Kölsche, Tristan, Korsen, Melanie, Grothe, Matthias, Groppa, Sergiu, Luessi, Felix, Engel, Sinah, Nelles, Gereon, Bonmann, Eckhard, Roick, Holger, Friedrich, Anke, Knorn, Philipp, Landefeld, Harald, Biro, Zoltan, Ernst, Michael, Bayas, Antonios, Menacher, Martina, Akgün, Katja, Kleinschnitz, Christoph, Ruck, Tobias, Ziemssen, Tjalf, Pul, Refik, Meuth, Sven G.
Format: Article
Language:English
Subjects:
Cognitive ability
Disease-modifying therapy
Lymphopenia
Multiple sclerosis
Multiple sclerosis therapie
Non-pharmacological intervention
Patients
Real-wolrd data
Secondary progressive multiple sclerosis
Siponimod
Sphingosine 1-phosphate
Substantia grisea
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!